What type of study is this?

This is a Quantitative Study study.

October 8, 2025JCO Oncology Practice

Understanding gaps in molecular testing practices for metastatic prostate cancer (mPC): A statewide quality improvement initiative.

View Full Paper

Ask AI

Bookmark

Authors

NANayef Hikmat Abdel-RazeqJacksonville College OMOsama MosalemSaint Luke's Health System SKSaivaishnavi KamathamJacksonville College

Discussion

Member takes

Implication

Quality improvement initiative reveals significant gaps in biomarker testing adherence in Florida institutions, suggesting urgent need for enhancements.

Key Points

Only 56.4% of practitioners consistently review molecular testing results during disease progression, impacting treatment decisions.
22.5% of respondents indicated their institutions do not fully comply with NCCN guidelines for molecular testing.
The study identified critical gaps in clinical decision support tools, with nearly all institutions lacking adequate resources.
38.5% of respondents reported a lack of standard processes for obtaining prior authorization for biomarker testing.

Cite This Study

Abdel-Razeq et al. (2025) studied this question.

synapsesocial.com/papers/68e6f342f8145af55aeaccb4 https://doi.org/10.1200/op.2025.21.10_suppl.465

View Full Paper

Ask AI

Bookmark

Implication

Quality improvement initiative reveals significant gaps in biomarker testing adherence in Florida institutions, suggesting urgent need for enhancements.

Understanding gaps in molecular testing practices for metastatic prostate cancer (mPC): A statewide quality improvement initiative.

Discussion

Member takes

Implication

Key Points

Cite This Study

Understanding gaps in molecular testing practices for metastatic prostate cancer (mPC): A statewide quality improvement initiative.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider